Disparities among US States in HIV-Related Mortality in Persons with HIV Infection, 2001–2007

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.
AIDS (London, England) (Impact Factor: 5.55). 01/2012; 26(1):95-103. DOI: 10.1097/QAD.0b013e32834dcf87
Source: PubMed


To examine interstate variation in US HIV case-fatality rates, and compare them with corresponding conventional HIV death rates.
Cross-sectional analysis using data on deaths due to HIV infection from the National Vital Statistics System and data on persons 15 years or older living with HIV infection in 2001-2007 in 37 US states from the national HIV/AIDS Reporting System.
State rankings by age-adjusted HIV case-fatality rates (with HIV-infected population denominators) were compared with rankings by conventional death rates (with general population denominators). Negative binomial regression determined case-fatality rate ratios among states, adjusted for age, sex, race/ethnicity, year, and state-level markers of late HIV diagnosis.
On the basis of 3,096,729 HIV-infected person-years, the overall HIV case-fatality rate was 20.6 per 1000 person-years [95% confidence interval (CI) 20.3-20.9]. Age-adjusted rates by state ranged from 9.6 (95% CI 6.8-12.4) in Idaho to 32.9 (95% CI 29.8-36.0) in Mississippi, demonstrating significant differences across states, even after adjusting for race/ethnicity (P < 0.0001). Many states with low conventional death rates had high case-fatality rates. Nine of the 10 states with the highest case-fatality rates were located in the southern United States.
Case-fatality rates complement and are not entirely concordant with conventional death rates. Interstate differences in these rates may reflect differences in secondary and tertiary prevention of HIV-related mortality among infected persons. These data suggest that state-specific contextual barriers to care may impede improvements in quality and disparities of healthcare without targeted interventions.

Download full-text


Available from: Stephen Gange, Sep 19, 2014
  • Source
    • "The goals of the qualitative interviews were threefold: (1) to ensure the questions contained in two stigma scales [39,40] were accurately understood in this population; (2) to identify sources of HIV stigma and acts of discrimination faced by PLHIV; and (3) to assess the impact stigma has on the lives, self-image, and behavior of participants. This qualitative research was part of a larger study which sought to compare and revalidate two existing HIV stigma scales [39,40] among a larger sample of PLHIV in middle Tennessee, a region representative of the epidemic in the south [21]. The results of the quantitative study are discussed elsewhere. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV stigma is a contributing factor to poor patient outcomes. Although HIV stigma has been documented, its impact on patient well-being in the southern US is not well understood. Thirty-two adults participated in cognitive interviews after completing the Berger HIV or the Van Rie stigma scale. Participant responses were probed to ensure the scales accurately measured stigma and to assess the impact stigma had on behavior. THREE MAIN THEMES EMERGED REGARDING HIV STIGMA: (1) negative attitudes, fear of contagion, and misperceptions about transmission; (2) acts of discrimination by families, friends, health care providers, and within the workplace; and (3) participants' use of self-isolation as a coping mechanism. Overwhelming reluctance to disclose a person's HIV status made identifying enacted stigma with a quantitative scale difficult. Fear of discrimination resulted in participants isolating themselves from friends or experiences to avoid disclosure. Participant unwillingness to disclose their HIV status to friends and family could lead to an underestimation of enacted HIV stigma in quantitative scales.
    Full-text · Article · Aug 2013 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review provides an overview of the current status of the global HIV pandemic and strategies to bring it under control. It updates numerous preventive approaches including behavioral interventions, male circumcision (MC), pre- and post-exposure prophylaxis (PREP and PEP), vaccines, and microbicides. The manuscript summarizes current anti-retroviral treatment options, their impact in the western world, and difficulties faced by emerging and resource-limited nations in providing and maintaining appropriate treatment regimens. Current clinical and pre-clinical approaches toward a cure for HIV are described, including new drug compounds that target viral reservoirs and gene therapy approaches aimed at altering susceptibility to HIV infection. Recent progress in vaccine development is summarized, including novel approaches and new discoveries.
    No preview · Article · Aug 2012 · Frontiers in Immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: On a number of leading health indicators, including HIV disease, individuals in the southern states of the United States fare worse than those in other regions. We analyzed data on adults and adolescents diagnosed with HIV infection through December 2010, and reported to the Centers for Disease Control and Prevention (CDC) through June 2011 from 46 states with confidential name-based HIV reporting since January 2007 to describe the impact of HIV in the South. In 2010 46.0 % of all new diagnoses of HIV infection occurred in the South. Compared to other regions, a higher percentage of diagnoses in the South were among women (23.8 %), blacks/African Americans (57.2 %), and among those in the heterosexual contact category (15.0 % for males; 88.5 % for females). From 2007 to 2010 the estimated number and rate of diagnoses of HIV infection decreased significantly in the South overall (estimated annual percentage change [EAPC] = -1.5 % [95 %CI -2.3 %, -0.7 %] and -2.1 % [95 % CI -4.0 %, -0.2 %], respectively) and among most groups of women, but there was no change in the number or rate of diagnoses of HIV infection among men overall. Significant decreases in men 30-39 and 40-49 years of age were offset by increases in young men 13-19 and 20-29 years of age. A continued focus on this area of high HIV burden is needed to yield success in the fight against HIV disease.
    No preview · Article · Nov 2012 · Journal of Community Health
Show more